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Abbreviations 
Ab/α Antibody 
AMPs Antimicrobial peptides  
α-2AP Alpha 2-antiplasmin 
BSA Bovine serum albumin 
C monocytes Classical monocytes 
Ca Calcium 
CFUs Colony forming units 
CLR C-type lectin receptors 
DAMPs Damage-associated molecular patterns 
DNA Deoxyribonucleic acid 
DMEM Dulbecco's Modified Eagle's medium 
EVs Extracellular vesicles 
FACS Fluorescence-activated cell sorting 
FDPs Fibrin degradation products 
FMO control Fluorescence minus one control 
FpA Fibrinopeptide A 
FpB Fibrinopeptide B 
GFP Green fluorescent protein 
LSM Laser scanning microscope 
MV Microvesicles 
MACS Magnetic-activated cell sorting 
NC monocytes Non classical monocytes 
NEAA Non-essential amino acids 
NLRs NOD-like receptors 
NOD Nucleotide oligomerization domain  
NKT cells Natural killer T cells 
NETs Neutrophil extracellular traps 
PAI-1 Plasminogen activator inhibitor-1 
PAI-2 Plasminogen activator inhibitor-2 
PAMPs Pathogen-associated molecular patterns  
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PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffer saline 
PLG Plasminogen 
PRRs Pattern Recognition Receptors 
ROS Reactive oxygen species 
STED Stimulated emission depletion 
SEM Scanning electron microscope  
TAMs Tumor-associated macrophages 
TAFI Thrombin activatable fibrinolysis inhibitor 
TEM Transmission electron microscopy 
TEG Thromboelastography 
TF Tissue factor 
TFPI Tissue Factor Pathway Inhibitor 
TLR Toll-like receptor 
tPA Tissue-type plasminogen activator 
uPA Urokinase-type plasminogen activator 
uPAR uPA receptor 
WT Wild type 
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I. Introduction  
I.1. Systemic bacterial infection 
Circulating bacteria, viruses or fungi can cause systemic infections. The infections trigger the 
innate intravascular immune system through pattern recognition receptors (PRRs) that recognize 
microbial components; so-called pathogen associated molecular patterns (PAMPs) and 
biomolecules from damaged tissues termed damage-associated molecular pattern molecules 
(DAMPs). PRRs are either cytoplasmic or membrane bound and consist of toll-like receptors 
(TLRs), nucleotide-binding oligomerization domain-(NOD) like receptors (NLRs) and c-type 
lectin receptors (CLRs)1,2. Altogether, they activate intravascular immune system. Sepsis 
represents a dysregulation of intravascular immunity as it is an unbalanced host response to a 
systemic infection which can lead to life threatening multi-organ failure. More than 30 million 
people are affected worldwide every year which causes 6 million deaths3. 
I.1.1. Intravascular immunity 
Intravascular immunity consists of humoral and cellular components and plays an important role 
in clearance of bacteria or other pathogens from the circulation.  
Humoral immune response. Humoral immune responses act through neutralization of pathogens 
by antibodies as produced by plasma cells and involves the binding of the antibodies to the 
pathogens as well as through activation on of the complement system.   
Antibodies: Antibodies can coat the pathogen also known as opsonization, which consequently 
promote uptake of pathogen by phagocytic immune cells. Furthermore, binding of antibodies to 
the pathogen can also activate the complement system which can lead to lysis of microorganisms 
by introducing pores in their cell walls with the use of membrane attack complex4,5. 
Complement activation: The complement system is a major component of the immune system 
which leads to generation of C3a and C5a, also known as anaphylatoxins and contributes to 
opsonization of pathogens as well as chemoattraction of immune cells for the removal of apoptotic 
and necrotic host cells. The production of C3a and C5a has pro-inflammatory effects, which can 
enhance for example the recruitment of platelets, neutrophils and monocytes to the site of injury or 
inflammation.  
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C3a and C5a receptors have diverse roles in sepsis as C3a binds to macrophage C3a receptor can 
decrease the initial infection in a murine polymicrobial sepsis model and C5a receptor antagonist 
administration enhanced survival in the same model 6. C5a signalling inhibition in various 
experimental studies using models such as Escherichia coli (E.coli) sepsis in baboons and 
abdominal sepsis in rats also suggested inhibitory effects of C5a in sepsis7. 
Cellular immune response. The cellular intravascular immune response acts through various 
immune cells including neutrophils, different types of monocytes, invariant natural killer cells 
(NKT), Kupffer cells and even endothelial cells which play important roles in the clearance of 
circulating bacteria and prevention of the bacterial dissemination to different organs via the blood 
stream. 
Neutrophils and NETs formation: Neutrophils are innate phagocytic cells that are one of the first 
cells to arrive at sites of pathogen colonisation or vessel wall injury. They provide protection 
against pathogens via phagocytosis, generation of reactive oxygen species (ROS) and neutrophil 
extracellular traps (NETs) and others8. They can also increase vessel permeability and have an 
impact on coagulation cascade by interacting with platelets. Platelet-neutrophil conjugate 
formation promotes early activation of neutrophils which leads to degranulation, increased tissue 
factor expression and thereby stimulates thrombus formation9. Neutrophils can contribute to 
pathologic venous and arterial thrombosis or 'immunothrombosis' by the release of NETs. NET 
release is emerging as a major contributor to thrombus formation in many pathologic situations 
such as sepsis and malignancy10,11. 
NETs are large extracellular, web-like structures consisting of DNA, histones and serine proteases 
and embody strong microbicidal properties. Two processes initiate formation of NETs known as 
NETosis: the cell death pathway and non-lytic NETosis. The cell death pathway involves 
disassembly of nucleus, chromatin condensation and plasma membrane rupture. During non-lytic 
NETosis, granule proteins and nuclear chromatin get secreted and accumulate extracellularly10. 
Besides, residual anucleated cytoplast of the neutrophils it still continues to engulf microorganisms. 
Monocytes: Monocytes are bone marrow derived circulating phagocytes which comprise 3-10% 
of leukocytes in humans and play a role in the cellular defence against pathogens, homeostasis and 
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tissue repair. Human monocytes are divided into 3 different subtypes in humans classical (C) 
(CD14++, CD16−), intermediate (CD14+, CD16+), and non-classical (NC) (CD14+, CD16++) 
monocytes. Murine monocytes are divided into two groups: C monocytes (CD115+ Gr1+) and NC 
(CD115+ Gr1-)12,13. 
C monocytes in humans comprise about 80–95% of circulating monocytes. These cells are highly 
phagocytic and are known to express a wide range of scavenger receptors. Intermediate monocytes 
comprise about 2–8% of circulating monocytes. Their functions include production of ROS, 
antigen presentation, support of the proliferation and stimulation of T cells, inflammatory 
responses, and angiogenesis. NC monocytes comprise about 2–11% of circulating monocytes. 
They are mobile in nature and crawl the endothelium in the search for injuries within the endothelial 
layer of blood vessels14. They can have proinflammatory functions as they secrete pro-
inflammatory cytokines in response to infection.  
Kupffer cells: In contrast to the other types of tissue macrophages they can engulf circulating 
bacteria or other pathogens directly from the blood stream. The pathogens get engulfed within the  
macrophages into membrane-bound vacuoles (phagosomes) which mature and are converted into 
a highly microbicidal organelle called phagolysosome15,16. Kupffer cells are resident macrophages 
which scan the foreign material transferred from the gastrointestinal tract via portal vein into liver 
vasculature. The specificity of phagocytosis induced by Kupffer cells also depends on opsonization 
of pathogens by antibodies and complement proteins17. 
I.1.2. Coagulation system and immunothrombosis 
Coagulation system: Recent work shows that apart from the complement system and immune 
cell-mediated phagocytosis intravascular coagulation participates in the response to circulating 
pathogen. The coagulation system comprises of two main pathways; intrinsic pathway (contact 
pathway) and extrinsic pathway (tissue factor (TF) pathway), which both lead to formation of 
fibrin. The intrinsic pathway is directed by contact with negatively charged surfaces, with XII and 
involves kininogen, and pre-kallikrein. Other cofactors of the intrinsic pathway are factor XI (FXI), 
factor IX (FIX) and factor VIII (FVIII). The extrinsic pathway is initiated by TF (CD142 or 
thromboplastin) which is a membrane spanning glycoprotein and usually exposed on extravascular 
cells like fibroblasts, epithelial cells, pericytes TF is also upregulated on monocytes and most 
probably on endothelial cells under infectious and inflammatory conditions. During endothelial 
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wall injury TF gets access to the blood circulation and interacts with coagulation factor FVII/VIIa 
which together activate factor X to factor Xa. The extrinsic tenase complex then activates FIX 
(FIXa) as well as factor II (prothrombin)18. Both the intrinsic and extrinsic pathways together 
activate the prothrombinase complex. The prothrombinase complex consists of FXa, FVa, calcium 
and negatively charged phospholipid membranes. Activation of prothrombinase complex causes 
the activation of the inactive zymogen prothrombin (factor II) to thrombin (factor II a). Thrombin 
then converts fibrinogen to fibrin and activates in a positive feedback loop factor XI, factor VII 
and as well as creates positive feedback for factor XIII. 
 
 
Figure 1: Structure of the fibrin molecule. (a) The fibrin structure has α chains; in green, β chains; in red, and γ chains; 
blue, disulphide bonds are emphasized as yellow spheres. Fibrin degradation fragments D and E are highlighted. 
Fragment X is formed from plasmin cleavage of the αC region. (b) Cartoon fibrin molecule: upon release of FpA and 
FpB by thrombin, knob A and knob B are exposed to bind the respective hole a and hole b. (c) Interaction of two fibrin 
molecules23,24. 
Thrombin converts fibrinogen to fibrin monomers by removal of the N-terminal fibrinopeptides A 
and B. The N- and C- terminals of these monomers join at E and D nodules, respectively.  
Fibrinopeptide A induces protofibril formation and hence helps in the aggregation of fibrin fibers 
(Fig. 1). During this aggregation, the E domain of one homodimer interacts with the D domain of 
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a second homodimer. This leads to the formation half of staggered fibrin threads within the 
thrombus19. 
 Factor XIIIa (FXIIIa) enhances the cross linking of fibrin at lysine residues and increase the 
stability of fibrin clots20. The interaction of fibrin with different immune cells can also influence 
the clot density and its mechanical properties. For instance, incorporation of platelets into fibrin 
scaffolds lead to compact and more stiff clot. Platelet and fibrinogen together can act as an active 
surface for the recruitment, attachment and activation of neutrophils or other phagocytic cells 21,22. 
Immunothrombosis. Microvascular fibrin formation, platelet and neutrophil recruitment, NET 
formation, as well as the activation of TF-positive monocytes at the site of pathogen adhesion 
during systemic infection can lead to immunothrombosis. One study where intravascular 
thrombosis was inhibited by using TF antagonist TFPI suggests that immunothrombosis is highly 
influenced by microvascular coagulation 25. 
Microvascular coagulation and its ability to promote immunothrombosis were found to entrap 
circulating bacteria, inhibit their invasion into perivascular tissue or to other tissues and induce 
killing of pathogens. Immunothrombosis might perform the bacterial killing by providing a 
platform for antimicrobial peptides as well as serine proteases like NE 26. However, uncontrolled 
immunothrombosis can induce excessive inflammatory response inside blood vessels during 
sepsis, which is known as disseminated intravascular coagulation27.  
I.1.3. Fibrinolysis  
Fibrinolysis is defined as the breakdown of fibrin clots by plasmin either on the thrombus surface 
or on cells expressing fibrinolytic receptors. Plasmin acts on C- domains in fibrin, removing a 
peptide bond from the N terminal domain of the b-chain and to cleave the coil connector of E and 
D- domains28 (Fig. 2). 
Plasmin is activated from its zymogen form plasminogen (PLG) by the action of two serine 
proteases: tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). tPA is 
mostly produced by endothelial cells and uPA is synthesized by  monocytes, macrophages and 
some epithelial cells 29. The enzymatic activity of tPA increases by 2 fold when present together 
with fibrin and PLG. On the other hand, uPA does not require fibrin as it acts directly on the open 
conformation of PLG 30, 31.  
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Figure 2: Fibrin fiber structure showing fibrinolytic binding and cleavage sites. Relative positions of plasmin cleavage 
sites, and tPA, PLG and α2AP binding sites are color coded23.  
uPA and tPA can be inhibited by plasminogen activator inhibitor-1 (PAI-1) (Fig. 3) 
 
Figure 3: Fibrinolysis and its inhibitors. uPA and tPA secreted from immune cells and endothelial cells, respectively, 
act on PLG and generate plasmin which in turn degrades fibrin to form fibrin degradation products (FDPs). α2AP, 
PAI-1 (red) together with TAFI act as main inhibitors of fibrinolysis. 
In addition, plasmin activity is controlled by circulating inhibitors like α2-antiplasmin (α2AP) and 
plasminogen activator inhibitor-2 (PAI-2). Fibrinolysis can also be counter regulated by thrombin 
activatable fibrinolysis inhibitor (TAFI). TAFI acts by removing C-terminal lysine and arginine 
from fibrin thus influencing the binding of plasminogen to fibrin 32 . 
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I.2. Immune response to tumor cells and their extracellular vesicles (EVs) 
Intravascular immunity not only responds to pathogens but also responds to circulating tumor cells 
and their vesicles. Hence, intravascular coagulation could be also triggered by tumor structures in 
the microcirculation. 
I.2.1. EVs 
 EVs are membrane bound particles which consists of various subtypes, including exosomes (50-
100 nm) formed via endosomal pathway, microvesicles (MVs) (0.1- 1µm) as a result of plasma 
membrane budding, and large oncosomes (1-10 µm) released by proliferating cancer cells. EV 
cargos appear to control basic cellular functions, communication between immune cells as well as 
the pathogenesis of multiple diseases like cancer 33. 
I.2.2. MVs and metastasis 
Unlike exosomes, MVs originate directly from plasma membrane of all cell types and are released 
via actin -myosin-driven fission into the extracellular space. MVs can establish cell-cell 
communications by transferring their cargoes, like proteins and microRNAs to the target cell, 
thereby modulating cellular functions even to distant regions of body. Differences in MV cargos 
are highly dependent on the cells where MVs originate from34.  
 
Figure 4: Tumor MVs and their various functions35. 
MVs are released under physiological conditions while excessive release of MVs is known to occur 
under pathological conditions. Notably, increased levels of MVs have been described in patients 
with different types of metastatic cancer. Tumor derived MVs have been proposed to participate in 
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enhancing tumor cells migration, angiogenesis, blood coagulation, tumor growth, extracellular 
matrix degradation and metastasis (Fig.4) 35. 
I.2.3. Intravascular immune system and metastasis  
Immune cells play an important role in identifying and killing circulating cancer cells, cell debris 
or their microvesicles. CD8+ T cells and natural killer (NK) cells are known to be cytotoxic for  
metastatic tumor cells36,. 37  Yet, tumor cells can manage to escape from the immune system and 
to extravasate38. Immunosuppression by tumor cells can be mediated by secreting 
immunosuppressive cytokines like IL-10 and TGF-β 39. Classical monocytes in mouse are also 
capable of promoting tumor growth 40.  
Macrophages, because of their plasticity tend to actively participate in metastasis. Tumor cells can 
manipulate anti-metastatic immune cells to become pro-metastatic as best demonstrated for tumor 
associated macrophages (TAMs). TAMs are most abundant cells in tumor microenvironment can 
secrete immunosuppressive cytokines. These immunosuppressive cytokines and chemokines could 
suppress CD4+ and CD 8+ cells directly as well as indirectly by recruiting Tregs. TAMs can also 
negatively influence T cell activity by depleting L-arginine in the tumor environment 41, 42.    
The role of tumor MV in tumor metastasis is still largely undefined. In particular it is unknown 
how they interact with intravascular immune cells and whether they can perform immune escape 
on the parent cells. 
 
 
 
 
 
 
 
 
16 
 
I.3. Objectives of study 
Intravascular immunity aims to restrict bacterial survival and dissemination during systemic 
bacterial infection. Microvascular coagulation is likely a major component of intravascular 
immunity. However, crucial aspects of intravascular coagulation during systemic infection are still 
unknown. Hence, in the present study the following points were assessed:  
• Immune cell recruitment implicated in microvascular coagulation during systemic bacterial 
infection. 
• Mechanisms of cellular and molecular counterregulation of microvascular thrombosis. 
• Role of T helper cells and NC monocytes during intravascular immunity. 
 
In its second part, this study deals with influence of pancreatic tumor MVs on the metastatic 
potential of pancreatic cancer cells as influenced by intravascular immunity. To understand the 
correlation between tumor MVs, immune cells and metastasis in detail, the following questions 
have to be addressed: 
• How do circulating tumor MVs interact with intravascular immune cells? 
• How do circulating tumor MVs extravasate and contribute to progression of metastasis? 
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II. Material and methods 
II.1. Material  
II.1.1. Equipment 
Equipment  Manufacturer 
Balance MC1 LC 620 S Sartorius (Göttingen, Germany) 
Cell culture incubator  Binder GmbH (Tuttlingen, Germany) 
Cell culture microscope  Carl Zeiss (Jena, Germany) 
Count chamber Neubauer Improved Brand (Wertheim, Germany) 
Culture Hood  Heraeus 
ELISA Reader Dynatech MR7000 Dynatech Laboratories 
UV LED laser Dymax 
Incubator (cell culture) Heraeus (Hanau, Germany) 
Lamin Air flow HLB 2472 Thermo Scientific (Braunschweig, Germany) 
Light microscope Axiovert 100 Zeiss (Jena, Germany) 
LSM 510 Meta  Zeiss (Jena, Germany) 
Mega centrifuge  Heraeus, Omnifuge 2.0 RS 
Micropipettes (10µl, 20µl, 100µl, 
200µl, 1000µl) Eppendorf (Hamburg, Germany) 
Multiphor II blotting device  Amersham Pharmacia Biotech 
Nano Drop Thermo Fisher Scientific (Schwerte, Germany) 
pH meter  HANNA instruments (Quebec, Canada) 
Pipet boy Integra-Bioscience (Biebertal, Germany) 
Pippets (5ml, 10ml) Omnilabs GmbH  Co. KG (Bremen, Germany) 
Fortessa   BD Biosciences 
Thermocycler  Biozyme, MiniCyclerTM, MJResearch 
Thrombelastograph  RoTEG Dynabyte GmbH 
Vortexer Sartorius (Göttingen, Germany) 
Water bath Julabo U3 Julabo Labortechnik (Allentown, USA) 
2 Photon  LaVision BioTec GmbH (Bielefeld, Germany) 
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II.1.2. Reagents and chemicals  
Substance Manufacturer 
Ampicillin sodium salt Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Bovine Serum Albumin (BSA) Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Dako Pen Dako Denmark, Glostrup, Denmark 
DAPI (4',6-diamidino-2-phenylindole) Thermo Fisher Scientific, Carlsbad, USA 
Ethanol denatured 99.8 % Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
FACS Buffer  BD Biosciences 
Glycerol Merk millipore 
KCl (Potassium chloride) Merck, Darmstadt, Germany 
KH2PO4 (Potassium dihydrogen 
phosphate) 
Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
NaCl (Sodium chloride) Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Na2HPO4 * 2 H2O (di-Sodium hydrogen 
phosphate dihydrate) 
Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Paraformaldehyd (PFA) Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Sucrose Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
  
 
II.1.3. Antibodies  
Antibody Conjugation Concentration host Source 
CD4 (Ultra-
LEAF) 
- 7 µg/ml rat Biolegend 
CD2 PE 1:100 rat Biolegend 
CD14 PacBlue 1:50 rat Biolegend 
CD16 PE-Cy7 1:50 rat Biolegend 
CD15 PE 1:50 rat Biolegend 
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CD19 PE 1:50 rat BD Biosciences 
CD36 - 3mg/kg rabbit BD Biosciences 
CD56 PE 1:100 rat Biolegend 
CD335 PE 1:100 rat Biolegend 
CX3CR1 - 1:100 rabbit Novus Biologicals 
E.coli LPS - 1:200 mouse Abcam 
E.coli LPS PE 1:100 mouse Self labelled 
F4/80 - 1:100 rat Abcam 
F4/80 - 1:400 rat Biolegend 
Fibrin - 1:100 mouse WAK 
GFP - 5 µg/ml rabbit Abcam 
HLA-DR FITC 1 µl/50 µl rat Biolegend 
LC3 A550 0,4 µg/ml rabbit Novus 
Ly6C A488 1:400 rat Thermofischer 
Ly6C - 1:400 rat Thermofischer 
Ly6G - 15 µg/ml rat BD Biosciences 
mouse IgG A594 2 µg/ml  Thermofischer 
RORγT - 1:100 rabbit Biorbyt 
Stabilin 2 - 5 µg/ml Mouse Kai Schledzewski 
Stabilin 2 PE 7 µg/ml, 10 µg/ml mouse Self labelled 
T-bet - 1:100 rabbit Antibodies-online 
tPA - 1:100 rabbit GeneTex 
uPA - 1:100 goat GeneTex 
uPAR - 1:400 goat R&D 
 
II.1.4. Buffers 
CaCl2 (Faktor Xa Formation; 50ml) 
225 mg CaCl2 .2H2O 
ddH2O  
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Ca/Hepes (TEG)  
10 mM Hepes 
100 mM CaCl2,  
ddH2O, pH 7.4  
PBS (Phosphate Buffered Saline) (1L) 
8 g NaCl 
0.2 g KH2PO4 
1.42 g Na2HPO4.2H2O 
0.2 g KCl 
Permabilisation/ Blocking-Buffer 
0.2 % Fish Skin Gelatin 
0.5 % BSA 
0.1 % Saponin   
TNC (Tri-Nitrium Citrate for blood drawing) 
3.68 g TNC 
100 ml H2O 
Blocking buffer 
1.5g BSA 
100 ml ddH2O 
Sterile filtered 
Resuspension buffer (1L) 
138 mM NaCl 
2.7 mM KCl 
12 mM NaHCO3 
0.4 mM NaH2PO4 
1 mM MgCl2.6H2O 
5 mM D-Glucose 
5 mM Hepes 
pH 7.35 
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II.1.5. Bacteria and cell lines 
Type Origin Source 
L3.6pl Human pancreatic cancer cell 
line 
Prof. Christiane Bruns, Klinik für Allgemein- 
Viszeral- und Gefäßchirurgie, Köln, D 
KCP Mouse pancreatic cancer cell line Dr. Hana Algül, II. Medizinische Klinik und 
Poliklinik, Klinikum rechts der Isar der TU 
München (München, D)  
THP1 Human DSMZ ACC 16, Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH 
(Braunschweig, D) 
 
 
 
II.1.6. Mouse models 
Type/ Name Source 
C57BL/6  Charles River 
Kaede-tg mice 
Prof. Samuel Huber, I. Medizinische Klinik und 
Poliklinik, UKE Hamburg, D 
CX3CR1-eGFP 
Prof. Steffen Massberg, Medizinische klinik und 
Poliklinik I., Klinikum der Universität, München, D 
UPAR-/- 
Prof. Karen Vanhoorelbeke, Kulak Kortrijk Campus, 
KU Leuven, Belgium 
PLG-/- 
Prof. Karen Vanhoorelbeke, Kulak Kortrijk Campus, 
KU Leuven, Belgium 
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II.2 Methods 
II.2.1. Preparation of bacteria 
E.coli K12 strain used in all experiments was GFP (green fluorescent protein) labelled and was 
grown overnight in 50 ml falcons with LB-medium and 100 µg/ml ampicillin. Next day the mixture 
has been centrifuged at 4000 rpm for 10 min and optical density (OD) was measured at 600 nm to 
estimate the bacterial number. For animal injections 3.2x108 bacteria were used. 
II.2.2. Animal experiments  
WT mice were usually obtained from Charles River and treated as per the guidelines of the local 
legislation on animal protection (Regierung von Oberbayern, Munich). The experiments were 
performed under pathogen free conditions at the animal facility of Walter Brendel Center. Some 
animal experiments were done at the animal facility of KU Leuven Kulak, Belgium and UKE 
Hamburg.  
The animals were infected with 3.2x108 E.coli via tail veil injection and the organs (liver, spleen, 
lung, kidney, heart, brain) and blood were collected after different time points (1 hr, 3 hr, 6 hr, 
24hr, and 48hr).The injection schemes for all the animal experiments are as follows: 
Scheme 1: WT mice, Infection model 
0hr ------------------------------------------------------------------------------------- 1hr/3hr/6hr/24hr/48hr 
E.coli injection -------------------------------------------------------------- sacrifice and organ collection.  
 
0hr----------------------------2hr---------------------------------------------------------------------------- 7hr 
Anti-MIF ab----------------E.coli injection------------------------------- sacrifice and organ collection. 
 
0hr----------------------------4hr-----------------------------------------------------------------------------7hr 
DNase1----------------------E.coli injection------------------------------- sacrifice and organ collection. 
 
0hr----------------------------24hr-------------------------------------------------------------------27hr/30hr 
CD4 ab----------------------E.coli injection-------------------------------- sacrifice and organ collection. 
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Scheme 2: (Knock-outs) 
0hr------------------------------------------------------------------------------------------3hr/6hr/18hr/24hr 
E.coli injection (tail vein) ---------------------------------------------------------------------------------x 
Scheme 3: (Kaede mice) 
0hr--------------------------12hr----------------------------------------------------------------------3hr/6hr 
Photoconversion ---------E.coli injection----------------------------------------------------------------x 
  
To investigate the microvascular coagulation and the immune cell recruitment neutralizing 
antibodies or proteins were administered before E.coli injections at time points 0 hr, 2 hr, 4 hr and 
24 h.  E.coli was injected at various time points as shown in the schemes and animals were 
sacrificed after 1-24 hr post infection.  
Kaede mice have photoconvertible fluorescence protein that changes from green to red upon 
exposure to UV light. These mice were submitted to surgery proceed for the small intestine 
exposition to photoconvert Th17 cell population in the small intestine. The small intestine was 
exposed to UV light by using Dymax LED UV laser for 1 min three times. After 24 hrs of surgery, 
E.coli was injected and organs were harvested at 3 hr or 6 hr post infection from these animals. 
Small part of each organ was kept in separate eppicups for CFU analysis and rest of the organ was 
fixed in 2% paraformaldehyde solution for 2 hr. The fixed organs were then transferred to 30% 
sucrose solution (to preserve GFP signal from Labelled bacteria) incubated overnight at 4˚C after 
which the organs were stored at -80˚C. 
 
II.2.3. CFUs 
After sacrificing the mouse, small part of each organ was weighed, homogenized in PBS with 
scalpel and then transferred to 15 ml falcon tubes with glass beads and 1ml PBS. The number of 
viable bacteria in the homogenates of organs was determined by plating 10 fold serial dilutions on 
LB plates. For liver and spleen, 1:100, 1:1000 and 1/10000 dilutions were made whereas, for all 
other organs 1:10 and 1:100 dilutions were made. Plates were stored at 37 ˚C overnight and CFUs 
were counted as amount per gram weight of organ.  
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II.2.4. Immunostaining of cryosections 
The organs were stored for at least 24 hr at -80˚C and then embedded in tissue tek at -20˚C inside 
the cryotome. Frozen sections were made ranging from 5 µm to 10 µm and collected on super frost 
glass slides. Cryosections from mouse liver were fixed in 4% PFA for 10 min, washed with PBS 
(3 times, 3 min each), blocked/permeabilized with 0.1% Triton X/1.5% bovine serum albumin 
(BSA) solution in PBS for 40 min and washed again. Unlabelled or labelled primary antibody was 
added to slides and incubated overnight. Next day after washing the slides were incubated with 
secondary antibody if required (2 µg/ml, 1 hr, 4˚C). 
In some cases, staining was done using macrophage-specific anti-F4/80 antibody (10 µg/ml; 
Abcam), followed by staining with Alexa546-labeled secondary antibody (2 µg/ml, Thermo Fisher 
Scientific). Sinusoids were labeled with Alexa488-primary labeled anti-stabilin2 antibody (5 
µg/ml; InVivo BioTech Services). The sections were mounted in Vectashield® with DAPI (Vector 
Laboratories) and analyzed by confocal microscopy. In other experiments, pre-metastatic clusters 
of tissue cells were counted at different time points (day 4, day 8 and day 14), and were defined as 
groups of at least 6 nuclei at a distance of < 2 µm from each other. For each experiment 10 randomly 
chosen consecutive visual fields were analyzed. Two methods of detections were used: (i) direct 
immunostaining wherein the antigen is directly detected by a primary antibody coupled with a 
fluorophore and (ii) indirect immunostaining in which case the antigen is detected by a primary 
antibody, which is in turn detected by a secondary antibody coupled with fluorophore. Draq5 or 
DAPI were used to stain the nucleus. The slides were then washed, mounted with glycerol and 
analysis was performed using confocal laser scanning microscope from Zeiss.  
 
II.2.5. Isolation of human monocytes via MACS 
All experiments with human blood donor were approved by the ethics commission of the medical 
facility of LMU. Blood from healthy donors was obtained and drawn into 20 ml syringe with 2 ml 
tri-sodium citrate solution and 13 µl hirudin solution. Blood was then transferred into 
centrifugation tubes and centrifuged at 1,300 rpm for 15 min without brake at room temperature 
(RT). The plasma was removed and the buffy coat diluted 1:2 with monocyte wash buffer. 50 ml 
Falcons were filled with 15 ml ficoll, the diluted buffy coat was layered on top and centrifuged at 
380 g for 25 min without break at RT. The middle layer containing the cells was isolated into 50 ml 
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resuspension in FACS buffer. C monocytes were stimulated by using LPS (100 ng/ml for 2.5hr) 
and  NC monocytes were stimulated using ORN R-0006-TLR7/8 agonist for 2.5hr and thereby 
used for various assays.  
II.2.7. Isolation of mouse Th17 cells  
The liver was cut into tiny pieces and put in to 15 ml tube containing 6 ml of collagenase buffer 
for 45 min at 37°C. After the collagenase incubation the liver was smashed with metal strainer, 
washed with PBS/1% FBS, followed by centrifugation at 1,600 rpm for 10 min. The pellet was 
resuspended in 4 ml 40% Percoll, laid carefully on top of 4 ml 67% Percoll and centrifuged at 400 
g for 20 min, (room temperature) with slow acceleration. After centrifugation, the T cells were 
taken out by a 1 ml pipet from the interphase and transferred into 50 ml falcon tubes. The falcon 
tubes were then centrifuged at 1500 rpm for 5 min and resuspended in PBS/1% FBS followed by 
cellular staining by FACS. First lymphocyte population was gated; second doublets were removed 
by using FSC-H and FSC-W. After setting gate 3 for Foxp3 positive and IL17a cells, in the next 
gate CD3 and CD4 positive cells were selected. In the next step, CD4 positive cells having 
expression of IL-17a were isolated. These cells define Th17 cells, which could further be isolated 
as anti-inflammatory or Pro- inflammatory Th17 phenotypes (Fig. 6).  
In some cases, the naïve CD4 positive cells and APCs were isolated from peripheral lymph nodes 
and spleen of mice followed by their differentiation to anti-inflammatory or pro-inflammatory 
Th17 cells. Peripheral lymph nodes and spleen were isolated and smashed through 100 µm strainer. 
Followed by washing with FACS buffer and spun down at 1500 rpm for 5 min. Magnetic sorting 
was performed with the pellet. Negative selection was performed using anti-CD25-biotin and anti-
CD44-biotin antibody, 15 min incubation on ice and spun down. Then streptavidin beads (40 µl 
beads/ml) were added and incubated for 30 min. Next, the suspension of cells was put through the 
MACS column which was previously hydrates and washed 3 times. Before the suspension was put 
on the column, it has to be filtered out using 45 µm strainer to avoid the collapse of the column. 
The eluted solution is CD4 positive cells, which again were incubated with CD4-streptavidin 
magnetic beads (100 µl/ml) for 30 min. Eluted solution had CD4 negative population and in the 
column was CD4 positive cell population. CD4 positive cells were then spun down and added to 
the 12 well plate with medium. For the APCs, CD3 selection was performed. CD4 negative 

28 
 
II.2.8. FACS analysis 
T cells were isolated from livers of E.coli infected and from non-infected Kaede mice, 3 hr post 
infected and 6 hr after infection using the same Percoll gradient as mentioned in the section II.2.7.  
 
Figure 7: Gating strategy used for analysis the translocation of Kaede photoconverted Th17 cells from small intestine 
into the liver and the lung. 
 
II.2.9. FXa formation assay 
To measure the procoagulant activity of different immune cells we performed a chromogenic assay 
detecting the generation of factor Xa. Once factor X gets activated to factor Xa, there is a colour 
change due to cleavage of chromogenic substrate S2222. Serial dilutions of the standard 
Thromborel-S (CSL Behring) were prepared followed by addition of 50 µl CaCl2 to each well of a 
96-well plate. Then to these wells 50 µl of standard or samples were added. A master mix of 
chromogenic substance S-2222, Beriplex (CSL Behring) and respective amount of resuspension 
buffer was prepared such that 100 µl of this mix could be pipetted into each well. The absorption 
was measured at 405 nm using a plate reader (softMAXpro). A cycle of 6 min was repeated for a 
total of 36 min and the final values were expressed as mU/ml. 
 
II.2.10. Thromboelastography (TEG) 
The procoagulant activity of different monocyte subsets in whole blood was analyzed using 
thromboelastography. The assay was performed in a specialized TEG pin and cup apparatus. To 
250 µl of whole blood 60 µl of solution of 30 mM CaCl2+ HEPES and 30 µl of sample (10,000 
cells of each monocyte subset) was added in each cup. Directly after, the coagulation will start and 
therefore the measurement needs to be started immediately. The whole TEG preparation needs to 
be done very carefully and fast, to get as reliable and best results as possible, because the TEG is 
very sensitive. The most important parameter of the clotting, given by the TEG, is for the current 
experiments the Clotting Time (CT). The CT-value is the time from the reaction start until the 
fibrin formation starts. Additionally, the Clot Formation Time (CFT) is given, showing the time 
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from the beginning of fibrin formation until the time when the clot has a size of 20mm. The 
Maximal Clot Firmness (MCF) stands for the maximum firmness of the clot in mm and the TEG 
can give the amplitude reached after 10 min (A10) and the respective times when those parameters 
are reached. When the measurement runs long enough, fibrinolysis can also be shown, for example 
via the Lysis Index 30 minutes after CT (LI 30) or the Maximal Lysis (ML) and the respective 
time.  
 
II.2.11. Plasmin activity assay 
To analyze the fibrinolytic activity of different immune cells a plasmin activity assay was 
performed. First a clot was prepared in 96 well plates with the use of 20 µl thrombin (4 U/ml), 60 
µl fibrinogen-plasminogen mix (fibrinogen 2.5 mg/ml and plasminogen 1 mg/ml), incubating it for 
37 min at 37°C. Afterwards chromogenic substrate of S-2251 (1.5 mmol/L) and immune cells were 
added and the O.D was measured every 10 minutes for 1 hr at 405 nm to check for the protease 
activity of plasmin associated with immune cells.  
II.2.12. Quantitative polymerase chain reaction  
RNA isolation: Isolated immune cells (stimulated or unstimulated, 107 cells) were lysed by 
resuspension in TRIzol (600 µl) and processed for RNA purification. RNA isolation was performed 
using the Direct-Zol RNA miniPrep Plus kit (Zymo Research). After following the instructions 
from the manufacturer the isolated RNA was stored in RNase/DNase free tubes at -80°C.  
First strand cDNA synthesis: cDNA synthesis has performed using 800 ng of total RNA and 1 µl 
of random hexamer primers. The mixture was incubated at 65°C for 5 min. After incubation the 
vial was transferred to ice. 4 μl of 5X Reaction Buffer, 1 μl of RiboLock RNase Inhibitor (20 U/μl), 
2 μl of 10 mM dNTP Mix and 1 μl of RevertAid M-MuLV RT (200 U/μl) were mixed in the 
indicated order and added to the RNA-mix, giving a total volume of 20 μl per sample. The vial was 
then heated up to 25°C for 5 min, followed by 60 min at 42°C, finally yields cDNA. 
qPCR amplification of first strand cDNA: The cDNA was diluted 1:10 with nuclease free water. 
A mix of 2.5 μl Premix Ex Taq Master Mix and 0.5 μl Sonda Taqman was prepared and added upto 
final volume of 3 μl in each well of a microplate. 2 μl of the diluted cDNA was added to the wells, 
giving a total volume of 5 μl per well. Analysis of qPCR QuantStudio Software V1.2 was used. All 
experiments were done in triplicates. 
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II.2.13. Two –photon intravital imaging 
Two-photon intravital imaging was used to image in real time the engulfment of E.coli and fibrin 
debris by CX3Cr1 GFP+ cells in liver sinusoids. Imaging was done using a multiphoton LaVision 
Biotech (Bielefeld, Germany) TrimScope II system connected to an upright Olympus microscope, 
equipped with a Ti:Sa Chameleon Ultra II laser (Coherent) tuneable in the range of 680 to 1080 
nm. Additionally, an optical parametric oscillator compact (OPO) connected to the laser was giving 
extended wavelength with the range of 1000 to 1600 nm, for the far-red dyes excitation. An 
objective  16 × water immersion (numerical aperture 0.8, Nikon) was used. Single images were 
acquired from 80 μm to 100 μm depth, with z-interval of 2 μm. 820 nm was used as an excitation 
wavelength, with 1024×1024 pixels and detected by PMTs (G6780-20, Hamamatsu Photonics, 
Hamamatsu, Japan). ImSpector Pro (LaVision) was used as acquisition software.  An 
environmental box maintained a stable 37°C environment. Mice were anaesthetized and mounted 
on a custom-built stage connected to a suck ring pump device to visualize the liver 
microcirculation. 
II.2.14. Cell culture 
Cell culture allows maintenance and growth of cells in an artificial environment. In this study the 
following cell lines were used: L3.6pl cell line, human pancreatic cancer cell line and KPC cell 
line, a mouse pancreatic cancer cell line which was isolated from genetically modified mice (LSL-
KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre). L3.6pl and KPC cell lines were cultured in high glucose 
DMEM medium (4.5 g/l) with 2.5% NEAA, 10% FBS and 1% pen/ strep and low glucose DMEM 
(1g/l) with 10% FBS, 2.5% NEAA, 2.5% vitamins and 1% pen-strep, respectively. All the cells 
were grown in cell culture flasks of various sizes as per requirement and maintained in an incubator 
with relative humidity, CO2; 5%, at a temperature of 37°C. 
 
II.2.15. Isolation of MVs 
For MV isolation from L3.6pl and KPC cells, both cell cultures were suspended from the petri 
dishes in low glucose DMEM (1g/l) with low FBS (2%) followed by collection of the supernatants. 
Afterwards supernatants were subjected to initial centrifugation at 1,300 rpm for 10 min without 
break to remove large cells. The pellet was discarded and the supernatant was then centrifuged at 
1,430 g for 20 min to get rid of large vesicles, cell debris and platelets. After centrifugation the 
supernatant was collected and again centrifuged (1,430 g for 20 min). The supernatant was 
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recovered and centrifuged at 17,750 g for 30 min. Supernatant was discarded and the pellet 
containing the MVs was resuspended and centrifuged at 17,750 g for 30 min. The pellet was 
recovered and resuspended in appropriate medium for further analysis.  
 
II.2.16. Protein estimation 
The amount of protein present was determined immediately after the end of experiment using an 
end point chromogenic assay (Bradford’s assay). Samples were resuspended in a minimum volume 
of 500 µl PBS. Serial dilutions ranging from 2 mg/ml to 0.03906 mg/ml were made using a standard 
protein solution of 2 mg/ml BSA.  5 µl of the standards and samples were added in triplicates to 
96-well plates. 25 µl of copper-alkali-tartrate solution A, which forms a complex with the proteins 
in the suspension, was added to each well. Then, 200 µl of solution B, which reduces the protein 
complex to generate blue color was added to each of the wells above. The absorbance was measured 
at 700 nm and protein concentration of the samples was calculated form the standard curve using 
excel scatter graph format. 
 
II.2.17. Electron microscopy  
To check the purity and quality of the MV preparations, the vesicle suspensions were fixed for 1 
hr. Fixation was performed using 2.5 % glutaraldehyde in 75 mM cacodylate buffer also containing 
2 mM MgCl2 and 2 mM NaCl. After fixation the samples were processed for transmission electron 
microscopy (TEM) and scanning electron microscopy (SEM). For TEM, 5 µl of the sample was 
applied to carbon-coated copper grids and negatively-stained with 2% uranyl acetate. For SEM, 
the fixed samples were frozen to glass slides with liquid nitrogen, washed 4 times with buffer (5, 
10, 30, 60 min), post-fixed with 1% aqueous osmium tetroxide for 1 h, washed again twice with 
buffer (10 min, overnight) and 3 times with double distilled water (5, 20, 30 min). After dehydration 
with a graded acetone series, the samples were critical-point-dried. The glass slides were mounted 
onto aluminum stubs and sputter-coated with platinum for 40 s. TEM was carried out on a Zeiss 
EM 912 at 80 kV. Images were acquired using a Tröndle 2k x 2k slow-scan CCD camera. For 
SEM, a Hitachi S-4100 SEM was used with the acceleration voltage set to 3 kV. 
II.2.18. Nanoparticle tracking analysis 
The isolated MVs were resuspended in PBS and applied to a ZetaView PMX 110 instrument by 
using a syringe. Different dilutions were made from each sample and all the samples were measured 
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at 11 different positions. Three cycles of reading were performed for each position. Polystyrol 
beads of known concentration and diameter (100 nm) were used for calibration. Post-acquisition 
parameters were set to a minimum brightness of 5, a resolution of 100 pixels and 30 frames/s.    
II.2.19. Animal experiments  
MVs (100 µg) protein were labelled with DiD and injected into the tail vein of WT mice (9- 12 
weeks). In some cases the animals were pre-treated with anti-CD36 antibody (3 mg/kg body 
weight) before injecting MVs. The injection scheme for the animal experiments was performed as 
described in scheme below: 
0-------------------------------------------------1h ------------------------------------------------------------2h  
Anti-CD 36 ----------------------------------MV/ PBS (100 µg) --------- sacrifice and organ collection.   
Long-term experiments were also performed, where the animals were sacrificed after 4 day, 8 days 
or 14 days after the MV and/ or cancer cell injections. 
0-----------------------10min-----------------1h--------------------------------------Day 4 / Day 8/ Day 14 
MV/ PBS (75 µg) + MV/ PBS (75 µg) --- Cancer cell inject----------- sacrifice and organ collection.     
During long-term experiments (up to 14 days) anti-CD36 antibody (3 mg/kg body weight) was 
infused every second day. 
II.2.20. Super-resolution microscopy 
Stimulated emission depletion (STED) nanoscopic imaging was used to double label the tumor 
MVs. SYTO RNASelect (500 nM, 20 min; Thermo Fisher Scientific), pHrodo (5 µM, 30 min; 
Thermo Fisher Scientific), DiD or Vybrant DiL were used to label the membrane and the 
intravesicular cargo of the MVs.  Human monocytic THP-1-cells were cultured in RPMI1640 
medium with 10 mM hepes (Merck) and 10% heat-inactivated FBS and were stimulated with PMA 
(300 nM, Merck) overnight to differentiate them into macrophages. Macrophages were then 
labelled with FM-464FX and incubated with double labeled tumor MVs for 60 min. After 60 min 
the cells were fixed with 2% PFA at 4°C for 15 min. Mounting was done using mowiol or Prolong 
Diamond Antifade Mountant (Thermo Fisher Scientific). The samples were analyzed using a Leica 
SP8 STED 3X (Leica, Germany). Images were reconstructed by using the LAS X software package 
(version 3.0; Leica, Germany) and deconvolution (CMLE algorithm) was introduced by using 
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Huygens Professional software package (version 16.10; Scientific Volume Imaging, the 
Netherlands). 
 
II.2.21. Statistics   
All mean values are given ± s.e.m. P values < 0.05 were considered to be significant. The results 
were compared by two-tailed unpaired t-test using Bonferroni corrections and Mann-Whitney rank-
sum test for multiple comparisons or one way ANOVA or two way ANNOVA. All-values given 
refer to different experiments or different animals. 
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III. Results  
III.1. Microvascular fibrin generation during systemic bacterial infection  
III.1.1. Infection kinetics and microvascular coagulation analysis in WT mice  
C57BL/6J mice were injected with 3.2 x 108 E.coli via the tail vein for the different time intervals 
(1 hr, 3 hr and 6 hr). To analyze the infection kinetics, CFUs were measured in the liver, spleen, 
kidney, lung, heart and the brain. 
a) 
 
b) 
 
Figure 8: Kinetics of systemic infection with E.coli.  a) CFU analysis in the E.coli infected liver after 1 hr, 3 hr and 6 
hr. b) CFU measurements in the liver, spleen, lung, heart and the brain at 3 hr post infection. n = 3-6; animal number 
per group. Mean +/- SEM. ** p <0.01, *** p <0.001. 
Fig. 8a shows a peak of infection in the liver occurred at 3 hr post infection. The liver and the 
spleen harboured the greatest amount of bacteria when compared to other organs (Fig. 8b).  This 
altogether confirms the role of the liver and the spleen as organs of immune tolerance and suggests 
that the resolution of the intravascular circulating E.coli starts potentially at 6 hr post infection.   
As a next step, to check for the localization of the bacteria in the liver microcirculation, we 
performed immunostaining of liver cryosections. Liver sinusoids were stained with anti-stabilin2 
antibody (orange), fibrin was visualized by using anti-fibrin antibody (red) and bacteria that 
genetically expressed the GFP (Fig 9a, b).  
Fibrin was quantified using the ZEN program by determining the total vessel area, as well as the 
area covered by fibrin inside the vessel. The analysed images showed that bacteria was entrapped 
by the fibrin in the microvasculature (Fig 9a). As shown in Fig. 9b, a method was developed and 
later being used for analysing the percentage of fibrin inside liver sinusoids.       
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Fibrin analyses show a peak of microvascular coagulation at the 3 hr time point (Fig. 10a and b) 
which suggests a possible correlation of a high bacterial number (Fig. 8a) with a high fibrin 
formation at 3 hr post infection.  
III.1.2. Infection kinetics and microvascular coagulation in gene-edited mice models  
III.1.2.1. Role of MIF during systemic bacterial infection  
Figure 11: a) CFU measurements in the liver 3 hr after infection in WT and MIF-/- mice.  b) CFU measurements in 
the spleen 3 hr after infection in WT and MIF-/- mice. C) Confocal images of fibrin formation in the liver of WT (left) 
and MIF-/- (right) mice at 3 hr post infection.  Arrows represent fibrin-rich areas inside the microvessels. Scale bars: 
20 µm. n = 5; animal number per group. Mean +/- SEM. ****p< 0.0001 
Fig. 11a and b indicate very strong effects of MIF on bacterial survival as the CFUs were massively 
reduced in both the liver and the spleen of MIF-/- mice when compared to WT mice. Fibrin 
To search for cytokine mediators of immunothrombosis we investigated the function of MIF, a pro-
inflammatory cytokine during systemic infection. The infection kinetics as well as fibrin formation 
were performed in mice deficient for MIF (MIF-/- mice). 
 
  
 
 
 
a) b) 
c) WT MIF-/- 
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formation was also influenced by MIF as the coagulation activation was clearly lowered in mice 
lacking MIF (Fig. 11c). 
III.1.2.2. Role of uPAR and PLG during systemic bacterial infection  
To reveal how the fibrinolytic system affects the systemic bacterial infection, E.coli was injected 
into uPAR-/- and PLG-/- mice. CFU analyses were done in the liver and spleen (Fig. 12a, b).   
a) 
 
b) 
 
Figure 12: a) CFU measurements in the liver 3 hr after infection in WT, uPAR-/- and PLG-/- mice.  b) CFU 
measurements in the spleen 3 hr after infection in WT control, uPAR-/- and PLG-/- mice. n = 4; animal number per 
group. Mean +/- SEM. ***p< 0.001, ****p< 0.0001 
Fig. 12a, b indicates the effect of uPAR and PLG on bacterial growth in both the liver and spleen. 
Bacterial survival is massively decreased at 3 hr when compared to WT animals. At the same time, 
representative pictures for fibrin formation (Fig. 13) show a marked increase of coagulation in 
uPAR-/- and PLG-/- mice. 
  
 
 
Figure 13: Representative images of fibrin formation in WT (left), uPAR-/- (middle) and PLG-/- (right) mice at 3 hr. 
Scale bars: 20 µm. n = 4; animal number per group.   
 
WT uPAR-/- PLG-/- 
Fibrin/DAPI Fibrin/DAPI Fibrin/DAPI 
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To check the effects of fibrinolysis at later time points, the experiments were also performed at 18 
hr after infection. CFUs were measured in the liver and the spleen (Fig. 14a, b).  
      a) 
      
     b) 
      
 
  
 
 
 
Figure 14: a) CFU measurements in the liver 18 hr after E.coli infection in WT control, uPAR-/- and PLG-/- mice.  b) 
CFU measurements in the spleen 18 hr after E.coli infection in WT control, uPAR-/- and PLG-/- mice. c) 
Representative pictures of fibrin formation in WT (left), uPAR-/- (middle) and PLG-/- (right) at 18 hr. Scale bars: 20 
µm. n = 4; animal number per group. Mean +/- SEM. *p< 0.05, ** p <0.01.  
 
Although less prominent, inhibition of fibrinolysis also increased bacterial elimination at 18 hr. 
Fig. 14 c shows an increased fibrin formation in uPAR-/- and PLG-/- as compared to WT mice at 
the 18 hr time point. 
Both after 3 hr and 18 hr also quantitative measurements of fibrin positive microvessels were 
performed (Fig. 15a, b).  The fibrin formation data (Fig. 15a) from WT, uPAR-/- and PLG -/- mice 
point towards the importance of fibrin in bacterial clearance since increased fibrin formation was 
associated with a reduced bacterial survival.  
c) 
WT uPAR-/- PLG-/- 
Fibrin/DAPI Fibrin/DAPI Fibrin/DAPI 
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Figure 15: a) Fibrin positive microvessels at 3 hr and 18 hr post infection in WT control, uPAR-/- and PLG-/- mice.  
b)  Percentage of occluded vessels (above 80%) at 3 hr and 18 hr post infection in WT control, uPAR-/- and PLG-/- 
mice. n = 4; animal number per group. Mean +/- SEM.  **** p <0.0001.  
Moreover, the increased occlusions of liver microvessels in uPAR-/- and PLG-/- mice compared 
to WT mice emphasize the role of fibrinolysis in maintaining blood perfusion in the 
microcirculation during systemic infection. 
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Figure 17: Immune cell recruitment to liver microvasculature at 3 hr post infection in WT control, uPAR-/- and PLG-
/- mice. n = 3-4; animal number per group. Mean +/- SEM. **p<0.01, ***p< 0.001, **** p <0.0001.  
In uPAR-/- and PLG-/- the influx of immune cells into the liver microvasculature was clearly 
changed (Fig. 17). The recruitment of neutrophils, C monocytes, Th1 cells and B cells was reduced, 
while the accretion of NC monocytes and Th17 was enhances in the liver microcirculation. 
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III.3. Fibrinolytic proteins 
Proteins like tPA or uPA are key players of fibrinolysis as they activate plasminogen to plasmin 
which further leads to degradation of fibrin. To visualize the time dependence of the cellular 
binding of uPA and its receptor uPAR in the liver microcirculation of infected mice, 
immunostaining was performed to detect cells positive for fibrinolytic proteins (Fig. 18a, b). 
Fig. 18a, b and c show a gradual increase of uPA and uPAR positive cells between 1 hr and 6 hr. 
A peak was revealed at 6 hr after infection.  
a) 
 
b) 
 
 
  
Figure 18: Time dependence of (a) uPA and (b) uPAR- positive cells at 1 hr, 3 hr and 6 hr after infection in WT mice. 
c) Representative pictures of uPA and uPAR positive cells at 6 hr. Scale bars: 20 µm. n = 3-4; animal number per 
group.  Mean +/- SEM. **p<0.01, **** p <0.0001.  
Furthermore, in comparable experiments the number of tPA positive cells were assessed (Fig. 19a). 
In addition cells positive for PAI-1 were imaged (Fig. 19b), which is a strong inhibitor of 
fibrinolysis. 
c) 
uPAR/DAPI uPA/DAPI 
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a) 
 
b) 
 
 
 
 
Figure 19: Time dependence of a) tPA and b) PAI-1 positive cells at 1 hr, 3 hr and 6 hr after infection in the liver 
microcirculation of WT mice. c) Representative pictures of tPA positive cells at 3 hr. Scale bars: 20 µm. n = 3-4; 
animal number per group. Mean +/- SEM. **p<0.01, ***p< 0.001, **** p <0.0001.  
Fig. 19a and c shows the time dependence of appearance of tPA positive cells. A peak is observed 
at 3 hr after infection. A peak of the appearance of PAI-1 positive cells is also observed after 3 hr 
(Fig. 19b). Thereafter PAI-1 disappear completely which coincides with the fall in fibrin formation 
after 6 hr (Fig.10a). 
 
 
 
 
 
 
   
TPA Stb2 TPA/Stb2/DAPI 
c) 
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III.4. Colocalization of distinct immune cells with fibrinolytic proteins 
To identify immune cells potentially involved in fibrinolysis during systemic bacterial infection, 
immunofluorescence staining was performed and colocalization of neutrophils, C monocytes, NC 
monocytes and CD4+ T cells with uPA (Fig. 20a) and uPAR (Fig. 20b) was analyzed at different 
time points. 
 
a)                                                                                       b) 
  
Figure 20: Colocalization of recruited immune cells with a) uPA and b) uPAR at 1 hr, 3 hr and 6 hr after infection in 
WT mice. n = 3-4; animal number per group. Mean +/- SEM. *p<0.05, ***p<0.001, **** p <0.0001.  
Fig. 20 a, and b show that colocalization of neutrophils with uPA and uPAR is maximal at 3 hr. At 
6 hr, NC monocytes and CD4 + T cells substantially colocalize with uPA and uPAR. C monocytes 
express uPAR receptor on their surface in particular at 6 hr. The strongest colocalization of uPA 
and uPAR with immune cells is seen with CD4+ T cells at 6 hr (Fig. 20a, b). 
III.5. CD4+ T cells during systemic bacterial infection 
III.5.1. Depletion experiments 
Given that CD4+ T cells were present in massive numbers at earlier time points (Fig. 16a) and 
strongly colocalized with uPA and uPAR (Fig. 20a, b)  , the next step was to analyze their role in 
systemic bacterial infection.  To this purpose Iso-IgG antibody or neutralizing anti-CD4 antibody 
(100 µg) was infused 24 hr prior to E.coli supplementation (scheme D, section: II.2.2.).  
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a) b) 
Figure 21: CFU measurements in Iso-IgG control injected mice and CD4 neutralizing ab injected mice at a) 3 hr and 
b) 6 hr after infection.  n = 3-4; animal number per group. Mean +/- SEM. **** p <0.0001.  
After 3 hr and 6 hr post infection we assessed CFUs in major organs. CFUs were reduced in the 
liver of CD4-depleted animals compared to Iso-IgG injected mice both at 3 hr (Fig. 21a) and more 
profoundly at 6 hr (Fig. 21b).  At 6 hr also splenic CFUs were diminished. Increased formation of 
fibrin was also analyzed in CD4-depleted animals as compared to the Iso-IgG control (data not 
shown). Furthermore, to identify the subtypes of CD4+ T cell recruited at 3 hr post infection; we 
performed staining with various antibodies. As a result, most of the CD4 + T cells were found to 
represent Th17 cells (Fig. 22).  
 
    
Figure 22: Identification of CD4+T cell subtype as Th17 cells in liver microvessels at 3 hr post infection (anti-CD4 ab-
488, anti-RORγt ab; secondary ab alexa fluor 594, anti-stb2 ab; secondary ab alexa fluor 550; pseudocolor in blue). 
Scale bar: 20 µm.  
 
 
CD4 RORΥT Stb2 CD4/RORΥT/Stb2 
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III.5.5. Il23R-/- mice experiments 
To analyze the role of Th17 cells for the outcome of the systemic infection we performed some 
experiments with IL23R-/- mice. CFUs were measured in E.coli injected IL23R-/- mice and WT 
mice after 6 hr of infection (Fig. 28).   
 
Figure 28: Bacterial survival in the liver of WT and IL23R-/- mice 6 hr after infection. n = 3-4; animal number per 
group. Mean +/- SEM. * p <0.05.  
FACS analyses of the livers of IL23R-GFP mice indicated that in these animals apart from Th17 
cells also γδ T cells, NKT cells and innate lymphoid cells were labelled (data not shown). 
Moreover, analyses of FACS data (not shown) suggested that most of the cells that were IL23R-
GFP positive were γδ T cells. Therefore, IL23R-/- mouse model was not further analyzed. 
However, Fig. 28 shows that IL23R positive cells are involved in bacterial killing.    
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III.6.2. Procoagulant activity of monocyte subsets 
To understand the role of different monocyte subsets for immunothrombosis, the subsets were 
isolated from healthy human blood using FACS sorting.  As a next step, TEG was performed in 
platelet poor plasma (PPP) with PBS (control), C monocytes (PPP+CD14) and NC monocytes 
(PPP+CD16) (Fig.31). 
 
Figure 31: Clotting time of platelet poor plasma without (black) and with (blue, purple) subsets of activated monocytes. 
n = 3; different experiments. Mean +/- SEM. **p<0.01.  
Fig. 31 shows a very low clotting time in samples containing stimulated C monocytes in accordance 
with a high pro-coagulant activity of these cells. In contrast, activated NC monocytes did not result 
in a significant increase in fibrin formation.  
FXa formation assays were used in addition to TEG to measure the procoagulant activities of 
monocyte subsets. In this case, both stimulated and unstimulated monocyte subsets were 
investigated (Fig. 32).   
 
Figure 32: FXa formation by unstimulated C monocytes (column 1), stimulated C monocytes (column 2), unstimulated 
NC monocytes (column 3) and stimulated NC monocytes (Column 4) n = 3-4; different experiments. Mean +/- SEM. 
**** p <0.0001.    
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The high values of FXa formation as induced by stimulated C monocytes confirmed their 
procoagulant activity compared to both unstimulated C monocytes and NC monocytes. Notably, 
stimulation of NC monocytes did not increase their ability to enhance factor Xa activation. 
III.6.3. Colocalization of NC monocytes with fibrinolytic proteins 
In view of these findings we went back to the in vivo situation to test whether NC monocytes would 
present fibrinolytic proteins on their surface that could confirm their coagulant activities. 
    
Figure 33: Expression of uPAR on the plasma membrane of NC monocytes after systemic infection with E.coli at 6 
hr. uPAR was visualized by anti-uPAR antibody (red) on NC monocytes which are negative for Ly6C (green) and 
positive for CX3CR1 (orange). Scale bar: 5 µm. 
Hence, we explored whether NC monocytes presented uPA or uPAR on their membrane surface 
during systemic infection. Fig. 33 shows that NC monocytes indeed expressed uPAR. Next, the 
numbers of NC monocytes being positive for uPAR (Fig. 34a) and uPA (Fig. 34b) were counted.  
a) 
 
b) 
 
Figure 34: Quantitative analysis of the co-localization of uPAR and uPA with NC monocytes from 6 hr to 48 hr after 
systemic bacterial infection.  n = 3-4; animal number per group. Mean +/- SEM. **p<0.01, *** p < 0.001.  
0
3
6
6hr 24hr 48hr
u
P
A
R
+
N
C
 m
o
n
o
c
y
te
s
***
**
0
3
6
6hr 24hr 48hr
u
P
A
+
N
C
 m
o
n
o
c
y
te
s
***
***
Ly6C uPAR CX3CR1 Merge 
53 
 
The results show a strong increase in uPAR and uPA positive NC monocytes from 6 hr to 48 hr 
that suggests a possible role of NC monocytes in fibrinolysis at later stages of the infection process.  
III.6.4. Fibrinolytic activities of monocyte subsets 
To test the abilities of different monocyte subsets to regulate fibrinolysis both mouse and human 
monocyte subsets were isolated and submitted to a chromogenic assay, that monitors plasmin 
activity by calculating the optical density at 405nm. 
  a)   b) 
Figure 35: Plasmin activity of monocyte subsets of (a) mouse and (b) human origin. Control without cells; St. NC and 
C monocytes represent the stimulated NC monocytes and C monocytes respectively, unst. NC and C monocytes 
represent unstimulated NC monocytes and C monocytes, respectively. Representable of total 3 different experiments.  
The results showed that stimulated NC monocytes, but not unstimulated NC monocytes or 
stimulated or unstimulated C monocyte, strongly support plasmin formation (Fig. 35a, b). 
III.6.5. Quantitative PCR 
Next, mRNA expression of uPA and uPAR was analyzed in human monocyte subsets. 
Quantification was based on internal reference genes to determine fold-differences in expression 
of the target gene.  
We observed an increase of the mRNA expression of uPAR and uPA mRNA 2 hr after stimulation 
of C monocytes and NC monocytes (Fig. 36a, b). 
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 NC monocytes had higher levels of uPA mRNA and of uPAR mRNA as compared to C 
monocytes. tPA m RNA was almost undetectable in both subtypes (data not shown) 
a) 
 
b) 
 
 
c) 
 
 
d) 
 
Figure 36: Quantification of gene expression of uPA and uPAR by qPCR in human monocyte subsets. n = 3;different 
experiments. Mean +/- SEM. **p<0.01, *** p < 0.001.  
 
 
 
 
55 
 
III.7. MVs and Metastasis 
Tumor cells secrete MV that circulate in the blood and may contribute to tumor progression. Here 
the intravascular immunity response to pancreatic tumor MV and the involvement of vesicles in 
pancreatic tumor metastasis were investigated.  
III.7.1. Characterization of MVs 
First, SEM and nanoparticle tracking analyses were performed to check if the isolated tumor 
vesicles is classified into the category of MVs.  
a) 
 
b) 
 
Figure 37: a) SEM of isolated vesicles released from L3.6pl pancreatic tumor cells. Scale bar, 500 nm. (B) Nanoparticle 
tracking analysis of size (diameter) distributions of isolated L3.6pl vesicles. 
SEM image analyses suggested a size of the isolated vesicles in the range of > 0.1 µm and < 0.5 
µm (Fig. 37a). Also, the spherical shape was typical of vesicles. Next the size of isolated vesicles 
was investigated by nanoparticle analyses; thereby it was confirmed that the diameter range of the 
particles was between 0.1 and 0.5 µm (Fig. 37b). 
III.7.2. Interactions of MVs with macrophages in vitro and in vivo   
The interactions of tumor MVs with macrophages in vitro were analyzed by using super-resolution 
microscopy. We were able to visualize separately the intravesicular area and the membrane of the 
same MV (Fig. 38a) with different markers, DCF for the MV membrane, SYTO RNASelect as 
well to stain the intravesicular cargo (see Methods). After the incubation of double labelled MV 
with macrophages intravesicular RNA accumulated in the cytoplasm of the acceptor cells (Fig. 
38b). Instead, the membrane marker colocalized with the macrophage cell membrane. 
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III.7.3. Role of CD36 for MV internalization into macrophages 
To characterize molecular mediators of the cellular uptake of MVs, we investigated the 
involvement of the class B scavenger CD36. Mice were supplemented with Iso-IgG type antibody 
or anti-CD36 neutralizing antibody followed by injection of DiD-labelled non-tumor MVs 
(circulating MVs) and tumor MVs.  
a) b) 
Figure 40: Quantitative analysis of the number of macrophages which engulf a) non-tumor MV and b) tumor MVs. 
Effect of Iso-IgG control and anti-CD36 neutralization in vivo. n = 3, animals per group. Mean +/- SEM ** p < 0.01.  
In mice infused with Iso-IgG antibody both non-tumor and tumor MVs accumulated in liver 
macrophages 1 h after MV injection. However, in mice treated with anti-CD36 antibody, MV 
incorporation by Kupffer cells was almost completely suppressed, suggesting that CD36 strongly 
contributed to cellular engulfment of non-tumor as well as tumor MVs (Fig. 40a, b).  
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III.7.4. MV extravasation  
We investigated whether MVs were transferred from the intravascular compartment to the 
perivascular/extravascular tissue. At D0 almost all MVs were localized in intravascular 
compartment of the liver microcirculation (Fig. 41).  Significant increases of MV fluorescence in 
the tissue occurred at D4, suggesting that the extravasation takes place between D0 and D4 
(Fig.41). 
 
Figure 41: Extravasation of tumor MVs. Quantitative analysis of MV fluorescence present in intravascular space (blue 
columns) and extravascular tissue (red columns).   n = 3; animal number per group. Mean+/- SEM. **p<0.01, *** p < 
0.001.  
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IV. Discussion 
In the first part of this thesis, microvascular immunity was analyzed during systemic bacterial 
infection. Systemic bacterial infection with E.coli was used as the main model for inducing 
intravascular infections, as circulating E.coli is a frequent inducer of systemic infections. An 
unlethal dose of E.coli was injected via the tail vein of mice and the infection kinetics was 
investigated at various time points in the liver and other organs. The rise in bacterial number until 
the 3 hr time point and a gradually decreasing bacterial survival thereafter suggests a strong efficacy 
of the intravascular immune system. The liver is known to be an immune-tolerant organ43 and in 
accordance with this we found that the survival of E.coli in the liver and the spleen was prolonged 
compared to other organs such as lungs or kidney.  
Various cytokines are known to directly or indirectly regulate coagulation and fibrinolysis during 
systemic infections and related clotting disorders44. Since the cytokine MIF plays an important role 
in systemic inflammatory immune responses, we analyzed its role in immunothrombosis. Previous 
work with a septic newborn mice, to which a small molecule inhibitor of MIF had been 
administered suggests that the cytokine can increase bacterial proliferation, systemic immune 
responses and the mortality of mice45. We largely observed similar results with respect to the 
infection kinetics in E.coli-infected MIF -/- mice, where the presence of MIF increased bacterial 
survival. Concomitantly, fibrin analyses performed on WT and MIF -/- mice suggested that MIF 
enhances fibrin formation.  
As a next step, to explore how coagulation affects bacterial survival, systemic E.coli infection were 
analyzed in mice with gene deficiency for uPAR and PLG. In uPAR-/- and PLG-/- mice, we 
observed significant increases in microvascular coagulation and vessel occlusion at 3 hr and 18 hr 
after infection. . At the same time points the levels of infection was measured in the liver and spleen 
of uPAR-/- and PLG-/- mice, showing decreased bacterial numbers compared to WT mice. This 
supports the view that intravascular coagulation supports the inhibition of fibrinolysis and an 
increased vessel occlusion is associated with an enhanced bacterial killing.  
To reveal the pattern of immune cell recruitment upon bacterial infection we analyzed the role of 
various immune cells in controlling or promoting coagulation in WT mice. Platelets were among 
the earliest cells to be recruited. Somewhat later (1 hr – 3 hr) CD4+ T cells specifically Th17 cells 
and NC monocytes appeared (6 hr).  The pattern of immune cell recruitment in uPAR-/- and PLG-
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/- mice suggest a major impact of fibrin on immune cell recruitment especially the one of Th17 
cells and NC monocytes. Based on these results we hypothesized that certain mobile immune cells 
can serve as counter regulators of immunothrombosis.  
The kinetics of appearance of immune cell-associated fibrinolytic proteins suggested a possible 
role of tPA and PAI-1 at the peak of fibrin formation. As the enzymatic activity of tPA increases 
from 100-1000 fold upon binding to fibrin46,23 the association with the peak of fibrin formation 
clearly indicates a strong tPA involvement in fibrinolysis at this time point. PAI-1 inhibits tPA and 
uPA. However, a PAI-1 inhibitor blocks thrombus formation in a mouse model of laser-induced 
vascular injury47. The peak of PAI-1 appearance at 3 hr suggests that it inhibits tPA at this time 
point and hence contributes to ensure a maximum of fibrin formation.  
Next, it was of critical importance to identify the immune cells being associated with fibrinolytic 
proteins. CD4+ T cells, C monocytes as well as NC monocytes were mostly associated with 
expressed uPA and uPAR, respectively. These findings encouraged us to uncover a possible role 
of CD4+ T cells and monocyte subsets during infection. When CD4+ T cells were depleted by 
neutralizing antibody the bacterial number at both 3 hr and 6 hr post infection were diminished. 
We next attempted to identify the subtype of CD4+ T cells involved in influencing coagulation. 
This lead to the characterization of Th17 cells as regulators of fibrin formation.  
Th17 cells are believed to be involved in immunity against intracellular bacterial infections induced 
by L. monocytogenes48, M. tuberculosis49,50, M. pneumoniae51and L. donovani52. Translocation of 
Th17 from gut to kidney has been observed in autoimmune kidney disease53. Hence, we 
hypothesized that during systemic bacterial infection Th17 cells might be translocated from the 
small intestine to the liver and other organs. To explore a potential recruitment of Th17 cells from 
the small intestine to the liver during infection photo-convertible Kaede mice were used. To track 
the Th17 trafficking from the small intestine to other organs, photoconversion was performed and 
analyzed by Flow cytometry. Flow cytometry analyses of the liver and the lung of infected and 
non-infected photoconverted Kaede mice suggested their translocation from the small intestine to 
the liver after 3 hr and 6 hr of infection. Immunofluorescence analyses of Th17 cells in the liver 
microcirculation pointed to the binding/expression of both fibrinolytic and procoagulant proteins. 
This, suggested plasticity in their role as regulators of intravascular coagulation as they expressed 
TF as well as uPA. Moreover, measurements of the plasmin formation activity of different Th17 
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phenotypes suggested that the anti-inflammatory phenotype of these cells has more fibrinolytic 
activity as compared to the pro-inflammatory phenotype.  
In contrast to C monocytes which were already recruited in the first 1 hr after infection, NC 
monocytes only appeared 6 hr or later during infection. To understand the potential role of NC 
monocytes during systemic infection, we determined their procoagulant activity in whole blood 
(human) and their ability to activate FX. The results show a rather low coagulant activity of NC 
monocytes as compare to C monocytes in vitro. In vivo analyses of uPA- and uPAR- association 
with immune cells indicated a colocalization with NC monocytes and thus suggested their role in 
fibrinolysis in the murine liver microcirculation. In vitro assays such as the plasmin formation assay 
supported the conclusion of their role in fibrin degradation. Moreover intravital microscope 
analyses of CX3CR1-GFP labelled mice suggested uptake of fibrin-coated bacteria by CX3CR1+ 
cells. Altogether, these findings strongly suggest a role of NC monocytes in the degradation of 
fibrin and of bacterial debris from the liver microcirculation of infected mice.  
Fig. 42 summarizes the principle findings of the first part of the thesis in relation to what is known 
about microvascular immunity in systemic bacterial infection. In the microcirculation of organs 
such as the liver, which is the site of various metabolic processes as well as site of major immune 
responses and of immune memory, circulating E.coli can be entrapped by microvascular 
coagulation which might be induced by for example TF expressed by C monocytes (Step I). TF 
expression especially on C monocytes leads to denser fibrin formation around the bacteria. Then 
adherent activated platelets enforce the recruitment of neutrophils. In step II, Neutrophil 
recruitment (as triggered by platelets) and additional immune cells like C monocytes, B1a cells and 
CD4+T cells are attracted. In step III bacteria are potentially killed directly by fibrin as formed 
around adherent the bacteria and the cytokines released by innate immune cells inside the fibrin 
clot. In step IV, NC monocytes are recruited together with B cells. NC monocytes may degrade 
fibrin and clear the bacteria from the circulation.   
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Figure 42: Hypothetical model: Schematic representation of the different steps involved in fibrin generation which 
mediates microvascular immunity in the liver during systemic bacterial infection.  The role of platelets, neutrophils, C 
monocytes and NC monocytes in the progression of infection are shown. Step (I) involves entrapment of bacteria by 
fibrin and platelets. During step (II), platelets are activated and neutrophils are recruited together with TF positive C 
monocytes and CD4+ T cells. (III) Elimination of live bacteria inside the fibrin rich microthrombus. (IV) Clearance of 
bacterial and host cell debris by NC monocytes from the microcirculation. 
In the second part of this work, the interaction of circulating tumor MVs with immune cells was 
investigated. MVs are generated by release from the plasma membrane through direct budding. 
Their size varies from 100 to 1000 nm54,55,56.  Nanoparticle tracking analysis and images generated 
by using SEM and TEM suggested the spherical shape and diameter range between >0.11 µm and 
< 0.5 µm which indicated the purity of the isolated MV.  
Since tumor MV were rapidly internalized by Kupffer cells in vivo we investigated how tumor MV 
interacted with macrophages in vitro. To this purpose, we used super-resolution microscopy to 
visualize separately for the first time the intravesicular compartment and the vesicle membrane of 
double labelled MVs. Following incubation of macrophages with tumor MVs, the vesicle 
membrane colocalized with the plasma membrane of the macrophages. Instead, the MV cargo was 
delivered to the macrophage cytoplasm. Together this suggested that in contrast to non-tumor MV, 
tumor MV had fused with the acceptor cell membrane. By delivering different RNA species to the 
interior of macrophage, the phenotype of the macrophages could be altered so that they might be 
converted to TAMs. Indeed, it has been reported that melanoma exosomes can promote 
polarization of M1 to M2 macrophage57. In the in vivo experiments extravasation of MVs took 
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place between days D0 to D4. Most of these MVs had been internalized by perivascular Ly6C- 
macrophages at D4 that clearly differ from Kupffer cells. These macrophages could be derived 
from C monocytes or from recruited NC monocytes58.  
According to the present study CD36 was found to participate in MV extravasation and their 
internalization by perivascular macrophage which is in line with the finding of a pro-metastatic 
effect of CD36 in oral cancer59. CD36 has also been discussed as a biomarker for metastasis in 
cancer60. Various studies suggest an increased expression of CD36 in human ovarian tumor61, 
gastric cancers62, glioblastoma63and oral squamous carcinoma64.  
Our results provide a mechanistic explanation of how CD36 might promote metastasis by showing 
that CD36 helps tumor MVs to extravasate to foster the formation of the pre-metastatic niche and 
of macroscopic metastasis. 
V. Video links 
1. Link 
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VI. Summary 
Intravascular immunity consists of humoral immune responses and cellular immune responses. It 
involves microvascular coagulation that can entrap circulating bacteria, reduce their dissemination 
and induce bacterial killing via immunothrombosis. To understand how intravascular coagulation 
participates in intravascular immunity during systemic bacterial infection we analyzed the immune 
cell recruitment in response to circulating E.coli in the blood stream.  
The results show that apart from innate immune cells such as C monocytes and neutrophils there 
is a massive recruitment of CD4+T cells and B1a cells to the infection sites in the liver 
microcirculation. By specifying the T helper cell fraction, we found that most of the CD4+T cells 
were Th17 cells. Next, we investigated the mechanisms involved in counterregulation of 
immunothrombosis. Here special emphasis was given to the fibrinolytic proteins associated with 
adherent immune cells during intravascular fibrin formation and to cytokines like MIF that are 
known to modulate systemic infections. Our findings suggested an important role of MIF for 
bacterial survival, which might be of relevance for the development of immunothrombosis. In 
uPAR-/- and PLG-/- mice microvascular coagulation was strongly increased which was associated 
with reduced bacterial survival. In parallel to this microvascular occlusion was increased 
substantially. Together this indicated a trade-off between protection from vessel occlusion and 
microbial killing.  Fibrinolytic proteins were mostly associated with Th17 cells and NC monocytes 
that were recruited in massive amounts during the peak and the resolution of fibrin formation 
respectively. Systemic infection experiments with Kaede mice suggested a rapid translocation of 
Th17 cells from the small intestine to the liver microcirculation. The recruitment of NC monocytes 
during the resolution of fibrin-rich microthrombi intrigued us to find out their specific role in 
systemic infection.  In vivo analyses, plasmin activity assays and RT-PCR suggested that these 
cells possess fibrinolytic properties and could possibly be recruited to clear the fibrin and/or cell 
debris in the microcirculation. 
Since intravascular immunity might be of substantial importance for the outcome of metastasis, we 
analyze its role in mice challenged with pancreatic tumor microvesicles or tumor cells.  EVs were 
isolated from human and murine pancreatic cell lines and characterized as microvesicles. 
Interactions of tumor MVs with immune cells were analyzed using in vitro and in vivo experiments. 
For the first time nanoscopic imaging was performed to monitor the unique transfer of MV cargo 
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to immune cells. Upon interaction with macrophages, the vesicle membrane was found to be 
associated with the cell membrane of the immune cells while the intravesicular cargo especially its 
RNA cargo, was transferred to the cytosol of the cell. This likely leads to changes in phenotypes 
of the immune cells consistent with the formation of TAMs. In-vivo experiments suggested the 
persistence of MVs inside perivascular Ly6C- macrophages which further participate in the 
formation of pre metastatic niches. Extravasation of tumor MVs was found to be mediated 
predominantly by the scavenger receptor CD36. CD36 neutralizing experiments in mice indeed 
suggested that CD36 promotes invasion of tumor MVs into different types of intravascular or 
perivascular macrophages. 
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VII. Zusammenfassung 
Die intravaskuläre Immunität setzt sich aus humoralen und zellulären Immunantworten zusammen. 
Sie beinhaltet auch die mikrovaskuläre Koagulation, welche zirkulierende Bakterien einfangen, 
deren Ausbreitung eindämmen und via Bildung von Immunothrombosen die Tötung der Bakterien 
induzieren kann. Um zu verstehen, wie intravaskuläre Koagulation an der intravaskulären 
Immunität während einer systemischen bakteriellen Infektion mitwirkt, haben wir die Rekrutierung 
von Immunzellen als Antwort auf zirkulierendes E.coli analysiert. 
 
Die Ergebnisse zeigen, dass, abgesehen von Zellen des angeborenen Immunsystems wie 
beispielsweise klassische Monozyten und Neutrophile, eine massive Rekrutierung von CD4+-T-
Zellen und B1a-Zellen in die Mikrozirkulation von infiziertem Gewebe der Leber stattfindet. Durch 
Spezifizierung der T-Helfer-Zell-Fraktion haben wir herausgefunden, dass der Großteil der CD4+-
Zellen Th17-Zellen waren. Daraufhin haben wir die an der Gegenregulation der Immunothrombose 
beteiligten Mechanismen erforscht. Hierbei lag das Augenmerk vor allem auf den fibrinolytischen 
Proteinen, die mit adhärierenden Immunzellen während der intravaskulären Fibrinbildung 
assoziiert waren, und auf Zytokinen, die bekannterweise an der Regulation von Infektionen 
beteiligt sind, wie MIF. Unsere Ergebnisse ließen auf eine wichtige Rolle des MIF für das 
Überleben von Bakterien schließen, was für die Bildung der Immunothrombose wichtig sein 
könnte. In uPAR-/- und PLG-/- Mäusen beobachten wir einen Anstieg der mikrovaskulären 
Koagulation, der mit einer reduzierten Bakterienzahl assoziiert war. Zudem kam es zu vermehrten 
mikrovaskulären Gefäßverschlüssen. Zusammengenommen deutet dies auf einen Zielkonflikt 
zwischen dem Schutz vor Gefäßverschlüssen und der Eliminierung der Pathogene. Fibrinolytische 
Proteine waren vor allem mit Th17-Zellen und nicht-klassischen Monozyten assoziiert, die auf 
massive Weise zu den jeweiligen Peaks der Fibrinbildung und -lyse rekrutiert wurden. Experimente 
mit systemischen Infektionen bei Kaede-Mäusen deuteten auf eine schnelle Translokation von 
Th17-Zellen aus dem Duenndarm in die Mikrozirkulation der Leber hin. Die Rekrutierung von 
nicht-klassischen Monozyten während der Lyse von fibrinreichen Mikrothromben hat uns 
veranlasst, mehr über deren spezifische Rolle in systemischen Infektionen herauszufinden. In vivo-
Analysen, Plasmin-Aktivitäts-Messungen und RT-PCR weisen darauf hin, dass diese Zellen starke 
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fibrinolytische Eigenschaften besitzen und möglicherweise rekrutiert werden, um Fibrin und/oder 
Zelldebris in der Mikrozirkulation zu beseitigen. 
Nachdem die intravaskuläre Immunität von außerordentlicher Bedeutung für den Ausgang von 
Metastasierung sein könnte, haben wir deren Rolle mithilfe von Mäusen, in die wir 
Pankreaskarzinomzellen oder deren Mikrovesikel (MV) injiziert haben, analysiert. Die Vesikel 
wurden aus menschlichen Pankreaskarzinomzelllinien sowie Pankreaskarzinomzelllinien von 
Mäusen isoliert und als MV charakterisiert. Interaktionen von Tumor-MV mit Immunzellen 
wurden sowohl mittels in vitro- als auch in vivo-Experimenten nachgewiesen. Zum ersten Mal 
wurden nanoskopische Aufnahmen durchgeführt, um den einzigartigen Transfer von MV-Cargo in 
Immunzellen zu beobachten. Es stellte sich heraus, dass sich infolge der Interaktion mit 
Makrophagen die Membran der Vesikel mit der Zellmembran der Immunzellen verbindet, während 
der Inhalt, besonders die RNA, in das Zytosol der Zelle transferiert wird. Dies führt möglicherweise 
zu Veränderungen im Phänotyp der Immunzellen und infolgedessen zur Bildung von TAMs. In 
vivo-Experimente zeigen das Verbleiben der MV innerhalb von perivaskulären Ly6C-
Makrophagen, welche daraufhin an der Bildung von prämetastatischen Nischen beteiligt sind. Wir 
haben außerdem herausgefunden, dass die Extravasation von Tumor-MV vor allem durch den 
Scavenger-Rezeptor CD36 herbeigeführt wird. CD36-neutralisierende Experimente mit Mäusen 
lassen in der Tat darauf schließen, dass CD36 die Invasion von Tumor-MV in verschiedene Typen 
von intravaskulären oder perivaskulären Makrophagen begünstigt. 
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